ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Approach to conversion of T4 monotherapy to combined T4 and T3 therapy[1]

Approach to conversion of T4 monotherapy to combined T4 and T3 therapy[1]
Current T4 therapy (mcg/day) Combined T4 and T3 oral therapy reflecting
a physiologic T4-to-T3 ratio of 13:1 to 16:1*
T4 oral dose (mcg/day) T3 dose
75 to 100 50 to 75 2.5 mcg twice daily
112 to 137 88 to 112

2.5 mcg three times daily

or

5 mcg AM and 2.5 mcg PM
150 to 175 112 to 137 5 mcg twice daily
200 to 250 150 to 200 7.5 mcg AM and 5 mcg PM
For patients in whom combined T4 and T3 therapy is pursued, the T4 and T3 components should be prescribed as separate levothyroxine and liothyronine pills according to the above conversions, which provide T4:T3 in a dose ratio that approximates normal physiology. Refer to UpToDate topic on treatment of primary hypothyroidism in adults for details, including patient selection considerations.
T4: levothyroxine; T3: liothyronine.
* Commercially available T4-T3 combination pills are a 4:1 ratio mixture that deliver a supraphysiologic T3 dose relative to T4 and are not suitable for providing a T4:T3 dose ratio that approximates the physiologic ratio shown in this table.
Reference:
  1. Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA guidelines: The use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012; 1:55.
Courtesy of Douglas S Ross, MD.
Graphic 112432 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟